The Bioxydyn team has expertise in MRI methods for quantifying tumour oxygen delivery, vascular status and cellularity. By providing unique non-invasive information our technologies can aid tumour characterisation and therapeutic decision making and help maximise results from small trial groups.
Tumour oxygenation and hypoxia
Tumour oxygenation levels play a critical role in tumour growth and response to intervention. Bioxydyn has world-leading expertise in the provision of non-invasive assessments of oxygen delivery to tumour tissue using oxygen-enhanced MRI (OE-MRI) methods that can be can be implemented easily in Radiology Departments.
Tumour microvasculature and angiogenesis
Angiogenesis and abnormalities of blood supply are hallmarks of cancer. Dynamic contrast-enhanced MRI (DCE-MRI) is an established approach for quantifying tumour microvascular status that has been applied in over 100 early-phase clinical trials to investigate anti-angiogenic and anti-vascular compounds. Bioxydyn has many years experience of providing robust DCE-MRI biomarkers for single and multi-centre clinical trials in cancer.
Tumour growth and therapy-induced shrinkage are reflected in the rate of cellular proliferation and death, respectively. Diffusion MRI is sensitive to changes in the packing of cells in tissues and is therefore increasingly applied in studies of tumour response to therapy. Bioxydyn has significant expertise in diffusion MRI quantification and standardisation for cancer imaging studies.